Study on the Therapeutic Effect and Prognosis of PD-1 Immunosuppressant in Patients with Chronic Lymphoblastic Leukemia
Objective To investigate the therapeutic effect and prognosis of programmed cell death 1(PD-1)immuno-suppressive therapy in patients with chronic lymphocytic leukemia(CLL).Methods 96 CLL patients were selected and were di-vided into the study group(n=48)and the control group(n=48)according to the random number method.The control group was given basic treatment measures,and the changes of ECG,liver and kidney function were noted;On the basis of the control group,the study group was treated with carrilizumab.The basic clinical data of the two groups were compared;T lymphocyte subsets in peripheral blood before and after treatment;Overall survival rate,complete remission rate and progression free survival;Adverse reactions.Results There was no significant difference in gender,mean age,WBC,absolute number of lymphocytes,percentage of lymphocytes,HGB,PLT and other clinical data between the 2 groups(P＞0.05).After treatment,the patients in the study group had CD3+,CD4+,CD4+/CD8+,inf-γ.The expression of IL-2 was higher than that before treatment and also higher than that in the control group(P＞0.05);But the expression of CD8+,NK,IL-4 and IL-5 was significantly lower than that of the control group(P＞0.05).The progression free survival of patients in the study group was significantly higher than that in the control group(P＞0.05),and the overall survival rate and complete remission rate were higher than those in the control group(P＞0.05)The to-tal adverse reaction rate of the study group was lower than that of the control group,but the difference was not significant(P＞0.05).Conclusion The efficacy and prognosis of PD-1 immunosuppressant in CLL patients are significantly better than that of conventional treatment,which can provide an effective reference value for the clinical treatment of this disease.
万方数据
维普
